Expression of CK-19, Galectin-3 and HBME-1 in the Differentiation of Thyroid Lesions: Systematic Review and Diagnostic Meta-analysis

Overview

Journal Diagn Pathol

Publisher Biomed Central

Specialty Pathology

Date 2012 Aug 15

PMID 22888980

Citations 47

Authors

Leandro Luongo de Matos

Adriana Braz Del Giglio

Carolina Ogawa Matsubayashi

Michelle de Lima Farah

Auro Del Giglio

Maria Aparecida da Silva Pinhal

Affiliations

Soon will be listed here.

Abstract

Background: To distinguish between malignant and benign lesions of the thyroid gland histological demonstration is often required since the fine-needle aspiration biopsy method applied pre-operatively has some limitations. In an attempt to improve diagnostic accuracy, markers using immunocytochemistry and immunohistochemistry techniques have been studied, mainly cytokeratin-19 (CK-19), galectin-3 (Gal-3) and Hector Battifora mesothelial-1 (HBME-1). However, current results remain controversial. The aim of the present article was to establish the diagnostic accuracy of CK-19, Gal-3 and HBME-1 markers, as well as their associations, in the differentiation of malignant and benign thyroid lesions.

Methods: A systematic review of published articles on MEDLINE and The Cochrane Library was performed. After establishing inclusion and exclusion criteria, 66 articles were selected. The technique of meta-analysis of diagnostic accuracy was employed and global values of sensitivity, specificity, area under the summary ROC curve, and diagnostic odds ratio (dOR) were calculated.

Results: For the immunohistochemistry technique, the positivity of CK-19 for the diagnosis of malignant thyroid lesions demonstrated global sensitivity of 81% and specificity of 73%; for Gal-3, sensitivity of 82% and specificity of 81%; and for HBME-1, sensitivity of 77% and specificity of 83%. The association of the three markers determined sensitivity of 85%, specificity of 97%, and diagnostic odds ratio of 95.1. Similar results were also found for the immunocytochemistry assay.

Conclusion: This meta-analysis demonstrated that the three immunomarkers studied are accurate in pre- and postoperative diagnosis of benign and malignant thyroid lesions. Nevertheless, the search for other molecular markers must continue in order to enhance this diagnostic accuracy since the results found still show a persistency of false-negative and false-positive tests.

Virtual Slides: Http://www.diagnosticpathology.diagnomx.eu/vs/3436263067345159.

Citing Articles

A Machine Learning-Based Model for Preoperative Assessment and Malignancy Prediction in Patients with Atypia of Undetermined Significance Thyroid Nodules.

Moon G, Park J, Lee T, Yoon J J Clin Med. 2025; 13(24.

PMID: 39768693 PMC: 11727776. DOI: 10.3390/jcm13247769.

Serum Anti-Thyroglobulin Autoantibodies Are Specific in Predicting the Presence of Papillary-like Nuclear Features and Lymphocytic Infiltrate in the Thyroid Gland.

Cabibi D, Giannone A, Bellavia S, Lo Coco R, Lo Bianco A, Formisano E Diagnostics (Basel). 2023; 13(12).

PMID: 37370937 PMC: 10297604. DOI: 10.3390/diagnostics13122042.

Immunohistochemistry in the pathologic diagnosis and management of thyroid neoplasms.

Crescenzi A, Baloch Z Front Endocrinol (Lausanne). 2023; 14:1198099.

PMID: 37324272 PMC: 10266214. DOI: 10.3389/fendo.2023.1198099.

Nrf2 as a novel diagnostic biomarker for papillary thyroid carcinoma.

Wang Z, Li J, Liu Z, Yue L Eur J Histochem. 2023; 67(2).

PMID: 36951264 PMC: 10080292. DOI: 10.4081/ejh.2023.3622.

Molecular Landscape of Pediatric Thyroid Cancer: A Review.

Guleria P, Srinivasan R, Rana C, Agarwal S Diagnostics (Basel). 2022; 12(12).

PMID: 36553142 PMC: 9776958. DOI: 10.3390/diagnostics12123136.

References

Saggiorato E, Aversa S, Deandreis D, Arecco F, Mussa A, Puligheddu B . Galectin-3: presurgical marker of thyroid follicular epithelial cell-derived carcinomas. J Endocrinol Invest. 2004; 27(4):311-7. DOI: 10.1007/BF03351054. View

Aratake Y, Umeki K, Kiyoyama K, Hinoura Y, Sato S, Ohno A . Diagnostic utility of galectin-3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules. Diagn Cytopathol. 2002; 26(6):366-72. DOI: 10.1002/dc.10111. View

Jones C, Athanasiou T . Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg. 2004; 79(1):16-20. DOI: 10.1016/j.athoracsur.2004.09.040. View

Coli A, Bigotti G, Zucchetti F, Negro F, Massi G . Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology. 2002; 40(1):80-7. DOI: 10.1046/j.1365-2559.2002.01304.x. View

Rydlova M, Ludvikova M, Stankova I . Potential diagnostic markers in nodular lesions of the thyroid gland: an immunohistochemical study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008; 152(1):53-9. DOI: 10.5507/bp.2008.008. View

Zhu X, Sun T, Lu H, Zhou X, Lu Y, Cai X . Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma. J Clin Pathol. 2010; 63(9):786-9. DOI: 10.1136/jcp.2010.076901. View

Saggiorato E, De Pompa R, Volante M, Cappia S, Arecco F, Dei Tos A . Characterization of thyroid 'follicular neoplasms' in fine-needle aspiration cytological specimens using a panel of immunohistochemical markers: a proposal for clinical application. Endocr Relat Cancer. 2005; 12(2):305-17. DOI: 10.1677/erc.1.00944. View

Ozolins A, Narbuts Z, Strumfa I, Volanska G, Gardovskis J . Diagnostic utility of immunohistochemical panel in various thyroid pathologies. Langenbecks Arch Surg. 2010; 395(7):885-91. DOI: 10.1007/s00423-010-0690-6. View

Prasad M, Pellegata N, Huang Y, Nagaraja H, de la Chapelle A, Kloos R . Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors. Mod Pathol. 2004; 18(1):48-57. DOI: 10.1038/modpathol.3800235. View

10.

Giannini R, Faviana P, Cavinato T, Elisei R, Pacini F, Berti P . Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens. Thyroid. 2003; 13(8):765-70. DOI: 10.1089/105072503768499662. View

11.

Zhu H, Qi J, Wang Y, Song Y, Zhang Z . Hyalinizing trabecular tumor and papillary carcinoma of the thyroid. Chin Med J (Engl). 2010; 123(20):2832-5. View

12.

Mijovic T, Gologan O, Rochon L, Hier M, Black M, Young J . Fine-needle aspiration biopsy of the thyroid: review of cytopathologic features predictive of malignancy. J Otolaryngol Head Neck Surg. 2009; 38(3):348-54. View

13.

Giorgadze T, Rossi E, Fadda G, Gupta P, LiVolsi V, Baloch Z . Does the fine-needle aspiration diagnosis of "Hürthle-cell neoplasm/follicular neoplasm with oncocytic features" denote increased risk of malignancy?. Diagn Cytopathol. 2004; 31(5):307-12. DOI: 10.1002/dc.20132. View

14.

Alexander E, Kennedy G, Baloch Z, Cibas E, Chudova D, Diggans J . Preoperative diagnosis of benign thyroid nodules with indeterminate cytology. N Engl J Med. 2012; 367(8):705-15. DOI: 10.1056/NEJMoa1203208. View

15.

Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A . Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med Res Methodol. 2006; 6:31. PMC: 1552081. DOI: 10.1186/1471-2288-6-31. View

16.

Liu Y, Morreau H, Kievit J, Romijn J, Carrasco N, Smit J . Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of.... Eur J Endocrinol. 2008; 158(3):375-84. DOI: 10.1530/EJE-07-0492. View

17.

Beesley M, McLaren K . Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology. 2002; 41(3):236-43. DOI: 10.1046/j.1365-2559.2002.01442.x. View

18.

Franco C, Martinez V, Allamand J, Medina F, Glasinovic A, Osorio M . Molecular markers in thyroid fine-needle aspiration biopsy: a prospective study. Appl Immunohistochem Mol Morphol. 2009; 17(3):211-5. DOI: 10.1097/PAI.0b013e31818935a9. View

19.

Martins L, Matsuo S, Ebina K, Kulcsar M, Friguglietti C, Kimura E . Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J Clin Endocrinol Metab. 2002; 87(10):4806-10. DOI: 10.1210/jc.2002-020094. View

20.

Kim M, Kim H, Hong S, Shong Y, Gong G . Diagnostic utility of galectin-3 in aspirates of thyroid follicular lesions. Acta Cytol. 2006; 50(1):28-34. DOI: 10.1159/000325891. View